Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of changes in gene expression upon CCI-006 treatment and resistance development of the MLL-rearranged leukaemia cell line PER-485

ABSTRACT: Analysis of changes in gene expression upon CCI-006 treatment and resistance development of the MLL-rearranged leukaemia cell line PER-485

PROVIDER: PRJNA476234 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression analysis of a MLL-rearranged leukaemia cell line, PER-485, treated with small molecule CCI-006.

Project description:A phenotypic cell-based high-throughput screen identified a novel small molecule, CCI-006 with selective cytotoxic activity against MLL-rearranged leukaemia cell lines. The aim of this experiment was to identify the mechanism of action of CCI-006 by investigating the gene expression changes induced in a MLL-rearranged leukaemia cell line following a short incubation with the compound.

2019-06-01 | GSE115793 | GEO

Analysis of gene expression changes in MLL-rearranged leukaemia cell lines with induced resistance against CCI-006

Project description:Gene expression analysis of two MLL-r leukaemia cell lines (SM6p2 and SM6p3) and the parental PER-485 MLL-rearranged leukaemia cell line they were derived from by continuous culturing in CCI-006. SM6p2 and SM6p3 thereby developed induced resistance against the compound. The aim of this experiment was to identify any gene expression changes in SM6p2 and SM6p3 cells induced by continuous culturing in CCI-006, thereby potentially providing insight into the mechanisms of primary and induced resistance of MLL-rearranged leukaemia cell lines against the cytotoxic compound CCI-006.

2019-06-01 | GSE115794 | GEO

Gene expression analysis of a MLL-rearranged leukaemia cell line, PER-485, treated with small molecule CCI-006.

Project description:Gene expression analysis of a MLL-rearranged leukaemia cell line, PER-485, treated with small molecule CCI-006.

| PRJNA476065 | ENA

Analysis of gene expression changes in MLL-rearranged leukaemia cell lines with induced resistance against CCI-006

Project description:Analysis of gene expression changes in MLL-rearranged leukaemia cell lines with induced resistance against CCI-006

| PRJNA476064 | ENA

Analysis of changes in gene expression upon CCI-006 treatment and resistance development of the MLL-rearranged leukaemia cell line PER-485

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-06-01 | GSE115833 | GEO

Human glioma cells treated with irradiation and/or CCI-779

Project description:Gene expression profiling of human glioma cell line LN-308. Cells were treated with the mTOR inhibitor CCI-779 or irradiated with a single dose of 4 Gy or a combination of both. The objective of this studywas to evaluate CCI-779 as a radio-sensitizing agent and to elucidate the underlying mechanisms. Irradiated, CCI-779-, DMSO- (vehicle control) or combination treated LN-308 samples were hybridized against pooled untreated LN-308 samples as reference (CCI+Irradiation vs. Ref; CCI vs. Ref; DMSO+Irradiation vs Ref; DMSO vs. Ref).Three independent replicates were generated for each treatment and control, respectively.

2011-09-19 | E-GEOD-24232 | biostudies-arrayexpress

PBMCs from CCI-779 Treated RCC subjects

Project description:Clinical Pharmacogenomics study. Renal Cell Carcinoma subjects were treated with CCI-779 and peripheral blood mononuclear cells were profiled over time of treatment. Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomics responses in patients with advanced renal cancer. Clin Pharm Therapeutics Dec 2004 Keywords: other

2004-12-01 | GSE1982 | GEO

Liver transcriptome analysis after DF-006 treatment in an HBV mouse model

Project description:A new chemical entity, DF-006, has been shown to suppress HBV replication in an AAV-HBV mouse model. DF-006 activates NF-kB signaling. In order to elucidate the mechanism of action of DF-006, specifically the genes expression stimulated in the liver that mediated its anti-HBV efficacy, we perform deep sequencing of RNA samples taken from AAV-HBV mice 4 hours after 10 μg/kg DF-006 oral administration or vehicle control. AAV-HBV mouse models were established by injecting male C57B6/J mice with 1011 vg/mouse AAV-HBV (genotype D, serotype ayw, GenBank accession number: KX449554). Dosing with DF-006 resulted in a statistically significant increase of gene expression for 1,685 genes in the liver. We performed an over-representation analysis for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and found 53 pathways were significantly enriched. The top 10 pathways included those that involved viral infection (e.g., herpes, influenza, Epstein-Barr, hepatitis B, measles) and those that involved host innate responses (TNF, osteoclast differentiation, NF-κB, toll-like receptor, RIG-I -like receptor). qPCR analysis confirmed genes that are directly or indirectly induced through NF-kB pathway and are reported before to play a role in HBV suppression.

2022-08-11 | GSE210856 | GEO

Coemansia sp. RSA 485 isolate:RSA 485

Project description:Coemansia sp. RSA 485 Resequencing genome sequencing

| PRJNA677041 | ENA

Rhizobium leguminosarum strain:SEMIA 485 | isolate:SEMIA 485

Project description:Rhizobium leguminosarum SEMIA 485 genome sequencing

| PRJNA581080 | ENA